Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
This bill makes comprehensive statutory changes to the 340B drug discount program. It (1) tightens and clarifies the definition of a qualifying “patient” and places limits on prescriptions from telehealth and non-covered providers; (2) creates new registration, eligibility, reporting, auditing, and transparency requirements for covered entities, child sites, contract pharmacies, and subgrantees; (3) establishes an HHS-contracted national clearinghouse to receive claim-level data from payors (Medicaid, Medicare, MA, PDPs) to detect duplicate discounts/rebates and other violations and requires covered entities and payors to submit detailed claim-level data; (4) requires patient affordability protections (sliding-fee caps on out-of-pocket costs) for eligible patients and bans extraordinary collection actions by certain hospitals; (5) limits fees for third-party administrators and contract pharmacies and authorizes civil monetary penalties for a range of violations; and (6) tightens hospital eligibility tied to enforceable contracts with state/local governments and charity-care thresholds.
Progressives emphasize patient affordability, charity-care protections, and transparency; conservatives emphasize program integrity, tighter eligibility, and limiting perceived abuses.
Relative to its intended legislative type, this bill is a detailed substantive statutory revision to the 340B program that specifies many operative mechanisms and accountability tools while delegating implementation specifics to the Secretary through rulemaking and a third-party clearinghouse contract.
This bill makes comprehensive statutory changes to the 340B drug discount program.
It (1) tightens and clarifies the definition of a qualifying “patient” and places limits on prescriptions from telehealth and non-covered providers; (2) creates new registration, eligibility, reporting, auditing, and transparency requirements for covered entities, child sites, contract pharmacies, and subgrantees; (3) establishes an HHS-contracted national clearinghouse to receive claim-level data from payors (Medicaid, Medicare, MA, PDPs) to detect duplicate discounts/rebates and other violations and requires covered entities and payors to submit detailed claim-level data; (4) requires patient affordability protections (sliding-fee caps on out-of-pocket costs) for eligible patients and bans extraordinary collection actions by certain hospitals; (5) limits fees for third-party administrators and contract pharmacies and authorizes civil monetary penalties for a range of violations; and (6) tightens hospital eligibility tied to enforceable contracts with state/local governments and charity-care thresholds.
Most provisions become effective one year after enactment, with some earlier or later effective dates specified.
Judged solely on content and historical legislative patterns, the bill is a high-impact, complex rewrite of a contested federal health program with substantial compliance, fiscal, and federalism implications. Such comprehensive, technical but distributive reforms typically face protracted committee review, intense stakeholder pushback, and negotiation. While parts (improved transparency, anti-duplication measures, patient affordability provisions) have cross-cutting appeal, the overall package—preemption clauses, strict eligibility tests, penalties, and a federal clearinghouse—makes final enactment unlikely unless substantially amended or paired with significant compromise measures.
Relative to its intended legislative type, this bill is a detailed substantive statutory revision to the 340B program that specifies many operative mechanisms and accountability tools while delegating implementation specifics to the Secretary through rulemaking and a third-party clearinghouse contract.
Progressives emphasize patient affordability, charity-care protections, and transparency; conservatives emphasize program integrity, tighter eligibility, and limiting perceived abuses.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize patient affordability, charity-care protections, and transparency; conservatives emphasize program integrity, tighter eligibility, and limiting perceived abuses.
A mainstream progressive would likely welcome the bill’s emphasis on patient affordability, transparency, and preventing program abuse.
The sliding fee scale caps, prohibition on extraordinary collection actions, and stronger reporting on how 340B margins are used align with priorities to protect low-income and uninsured patients and to ensure program dollars support care.
However, they would be cautious about any provision that could shrink safety-net coverage—e.g., deregistration rules or strict telehealth limits—that could reduce access if implemented without safeguards.
A pragmatic moderate would generally view the bill as a substantive attempt to strengthen program integrity while maintaining its safety-net purpose.
They would appreciate transparency, anti-duplication mechanics, and patient affordability measures, but worry about administrative burden, implementation complexity, and possible unintended effects on provider participation or drug access.
They would likely seek clearer phased implementation, cost estimates, and mechanisms to reduce compliance friction for smaller providers.
A mainstream conservative would likely support the bill’s emphasis on stopping duplicate discounts, tightening eligibility (especially restricting large nonhospital entities or affiliates), limiting contract pharmacy fees, and increasing audit and enforcement authority to prevent perceived abuses of the 340B program.
At the same time, they may object to new federal mandates on sliding fee scales, reporting requirements, preemption of state law, and additional federal bureaucracy (clearinghouse and expanded HHS audit authority).
They would be concerned about regulatory complexity and the potential for the statute to expand federal administrative power in ways that affect private contracts and insurer practices.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Judged solely on content and historical legislative patterns, the bill is a high-impact, complex rewrite of a contested federal health program with substantial compliance, fiscal, and federalism implications. Such comprehensive, technical but distributive reforms typically face protracted committee review, intense stakeholder pushback, and negotiation. While parts (improved transparency, anti-duplication measures, patient affordability provisions) have cross-cutting appeal, the overall package—preemption clauses, strict eligibility tests, penalties, and a federal clearinghouse—makes final enactment unlikely unless substantially amended or paired with significant compromise measures.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize patient affordability, charity-care protections, and transparency; conservatives emphasize program integrity, tighte…
Judged solely on content and historical legislative patterns, the bill is a high-impact, complex rewrite of a contested federal health prog…
Relative to its intended legislative type, this bill is a detailed substantive statutory revision to the 340B program that specifies many operative mechanisms and accountability tools while delegating implementation spe…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.